NUCLEIC ACIDS RESEARCH-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2092121, encodeId=ffa72092121f0, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志是好杂志，但是运气好遇到好的编辑，文章还是有戏的。大部分肿瘤基础研究，被编辑不适合发表在这个杂志而拒你。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:08:41 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242702, encodeId=24ae1242e0241, content=偏重的研究方向：生命科学 经验分享：NAR的效率是真的高，一审两个礼拜就结束了。给了半年修改，返稿之后半天就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6aac5396279, createdName=ms2000000482637756, createdTime=Fri Sep 02 03:10:37 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242046, encodeId=2d661242046e5, content=偏重的研究方向：感染学;分子诊断 经验分享：昨天投稿目前在编辑审核阶段忐忑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=85a68298213, createdName=ms5000001540302513, createdTime=Tue Aug 30 14:13:13 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227981, encodeId=24ca122e98173, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转录因子 经验分享：整天看别人写经验，今天也分享一个。最近投了一篇，很快送外审。外审3周后reject，还没有看到意见，老板出差了。本来想着应该可以修回的，不知道哪里的问题，自我感觉工作还是挺细致的，nature级别的创新性谈不上，但也首次报道了不少发现。估计NAR影响因子不断推高，现在投稿难度相对大了。准备试试其它几个10分以上的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Wed Jun 22 12:56:12 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532867, encodeId=9ce753286e35, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：老牌杂志，评审质量不用说。 2016/10/23凌晨投稿，当天peer-review。 2016/11/16返回审稿意见，一审三周。3个审稿人，问题一大推，不过都是一些值得讨论的问题，总体算是小修。 2017/01/17提交response。慢悠且谨慎的回答了两个月。编辑部来信催稿，就提交了。 2017/02/12返回二审意见（三周），3个审稿人的意见都是quite positive，主编accept。 之前投PNAS被拒，选择NAR主要是因为方向对口且审稿快。 杂志对创新性要求极高，文章机制要明确，内容要夯实，故事要完整。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=630, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60061655700, createdName=Liu Pilong, createdTime=Wed Feb 15 17:08:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005759, encodeId=90211005e59ab, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:3800.0 偏重的研究方向：核酸酶 经验分享：审稿超快，三周审完，修回后一天直接接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210616/5e9e8fc68e154194bb66963fec5de5fe/34d9ec5bc5cf456a8307b5c155f2028c.jpg, createdBy=67fc2107291, createdName=573611573_71677993, createdTime=Sat Aug 07 10:02:52 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074738, encodeId=c38210e4738c1, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：生物信息学;癌症;生命科学 经验分享：要是能在这个杂志发一篇觉得挺牛的，中国人发表不到8%，还是很难发的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 28 11:37:44 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565173, encodeId=9e735651e3f0, content=in editorial review这个状态需要多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Fri Jan 04 00:00:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972732, encodeId=81fd9e2732b3, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：核酸检测;遗传学与生物信息学 经验分享：我们实验室审了两轮被拒，最后发到了nc。这个期刊很难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=复旦生科院呵呵, createdTime=Fri Jun 11 07:18:19 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968269, encodeId=cb2d968269dc, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：机制明确;癌症;生物信息学 经验分享：至少我们癌症领域很难发，送审率不足10%！之前我们投稿3篇，只送审一篇，有幸中了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=北大科研初学者, createdTime=Mon May 24 22:41:24 CST 2021, time=2021-05-24, status=1, ipAttribution=)]

2022-10-06 slientwo

审稿速度:2.0 | 投稿命中率:25.0
经验分享：杂志是好杂志，但是运气好遇到好的编辑，文章还是有戏的。大部分肿瘤基础研究，被编辑不适合发表在这个杂志而拒你。

112 0

[GetPortalCommentsPageByObjectIdResponse(id=2092121, encodeId=ffa72092121f0, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志是好杂志，但是运气好遇到好的编辑，文章还是有戏的。大部分肿瘤基础研究，被编辑不适合发表在这个杂志而拒你。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:08:41 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242702, encodeId=24ae1242e0241, content=偏重的研究方向：生命科学 经验分享：NAR的效率是真的高，一审两个礼拜就结束了。给了半年修改，返稿之后半天就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6aac5396279, createdName=ms2000000482637756, createdTime=Fri Sep 02 03:10:37 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242046, encodeId=2d661242046e5, content=偏重的研究方向：感染学;分子诊断 经验分享：昨天投稿目前在编辑审核阶段忐忑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=85a68298213, createdName=ms5000001540302513, createdTime=Tue Aug 30 14:13:13 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227981, encodeId=24ca122e98173, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转录因子 经验分享：整天看别人写经验，今天也分享一个。最近投了一篇，很快送外审。外审3周后reject，还没有看到意见，老板出差了。本来想着应该可以修回的，不知道哪里的问题，自我感觉工作还是挺细致的，nature级别的创新性谈不上，但也首次报道了不少发现。估计NAR影响因子不断推高，现在投稿难度相对大了。准备试试其它几个10分以上的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Wed Jun 22 12:56:12 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532867, encodeId=9ce753286e35, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：老牌杂志，评审质量不用说。 2016/10/23凌晨投稿，当天peer-review。 2016/11/16返回审稿意见，一审三周。3个审稿人，问题一大推，不过都是一些值得讨论的问题，总体算是小修。 2017/01/17提交response。慢悠且谨慎的回答了两个月。编辑部来信催稿，就提交了。 2017/02/12返回二审意见（三周），3个审稿人的意见都是quite positive，主编accept。 之前投PNAS被拒，选择NAR主要是因为方向对口且审稿快。 杂志对创新性要求极高，文章机制要明确，内容要夯实，故事要完整。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=630, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60061655700, createdName=Liu Pilong, createdTime=Wed Feb 15 17:08:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005759, encodeId=90211005e59ab, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:3800.0 偏重的研究方向：核酸酶 经验分享：审稿超快，三周审完，修回后一天直接接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210616/5e9e8fc68e154194bb66963fec5de5fe/34d9ec5bc5cf456a8307b5c155f2028c.jpg, createdBy=67fc2107291, createdName=573611573_71677993, createdTime=Sat Aug 07 10:02:52 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074738, encodeId=c38210e4738c1, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：生物信息学;癌症;生命科学 经验分享：要是能在这个杂志发一篇觉得挺牛的，中国人发表不到8%，还是很难发的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 28 11:37:44 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565173, encodeId=9e735651e3f0, content=in editorial review这个状态需要多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Fri Jan 04 00:00:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972732, encodeId=81fd9e2732b3, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：核酸检测;遗传学与生物信息学 经验分享：我们实验室审了两轮被拒，最后发到了nc。这个期刊很难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=复旦生科院呵呵, createdTime=Fri Jun 11 07:18:19 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968269, encodeId=cb2d968269dc, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：机制明确;癌症;生物信息学 经验分享：至少我们癌症领域很难发，送审率不足10%！之前我们投稿3篇，只送审一篇，有幸中了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=北大科研初学者, createdTime=Mon May 24 22:41:24 CST 2021, time=2021-05-24, status=1, ipAttribution=)]

2022-09-02 ms2000000482637756

偏重的研究方向：生命科学
经验分享：NAR的效率是真的高，一审两个礼拜就结束了。给了半年修改，返稿之后半天就接收了。

73 0

[GetPortalCommentsPageByObjectIdResponse(id=2092121, encodeId=ffa72092121f0, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志是好杂志，但是运气好遇到好的编辑，文章还是有戏的。大部分肿瘤基础研究，被编辑不适合发表在这个杂志而拒你。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:08:41 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242702, encodeId=24ae1242e0241, content=偏重的研究方向：生命科学 经验分享：NAR的效率是真的高，一审两个礼拜就结束了。给了半年修改，返稿之后半天就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6aac5396279, createdName=ms2000000482637756, createdTime=Fri Sep 02 03:10:37 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242046, encodeId=2d661242046e5, content=偏重的研究方向：感染学;分子诊断 经验分享：昨天投稿目前在编辑审核阶段忐忑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=85a68298213, createdName=ms5000001540302513, createdTime=Tue Aug 30 14:13:13 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227981, encodeId=24ca122e98173, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转录因子 经验分享：整天看别人写经验，今天也分享一个。最近投了一篇，很快送外审。外审3周后reject，还没有看到意见，老板出差了。本来想着应该可以修回的，不知道哪里的问题，自我感觉工作还是挺细致的，nature级别的创新性谈不上，但也首次报道了不少发现。估计NAR影响因子不断推高，现在投稿难度相对大了。准备试试其它几个10分以上的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Wed Jun 22 12:56:12 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532867, encodeId=9ce753286e35, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：老牌杂志，评审质量不用说。 2016/10/23凌晨投稿，当天peer-review。 2016/11/16返回审稿意见，一审三周。3个审稿人，问题一大推，不过都是一些值得讨论的问题，总体算是小修。 2017/01/17提交response。慢悠且谨慎的回答了两个月。编辑部来信催稿，就提交了。 2017/02/12返回二审意见（三周），3个审稿人的意见都是quite positive，主编accept。 之前投PNAS被拒，选择NAR主要是因为方向对口且审稿快。 杂志对创新性要求极高，文章机制要明确，内容要夯实，故事要完整。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=630, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60061655700, createdName=Liu Pilong, createdTime=Wed Feb 15 17:08:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005759, encodeId=90211005e59ab, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:3800.0 偏重的研究方向：核酸酶 经验分享：审稿超快，三周审完，修回后一天直接接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210616/5e9e8fc68e154194bb66963fec5de5fe/34d9ec5bc5cf456a8307b5c155f2028c.jpg, createdBy=67fc2107291, createdName=573611573_71677993, createdTime=Sat Aug 07 10:02:52 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074738, encodeId=c38210e4738c1, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：生物信息学;癌症;生命科学 经验分享：要是能在这个杂志发一篇觉得挺牛的，中国人发表不到8%，还是很难发的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 28 11:37:44 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565173, encodeId=9e735651e3f0, content=in editorial review这个状态需要多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Fri Jan 04 00:00:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972732, encodeId=81fd9e2732b3, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：核酸检测;遗传学与生物信息学 经验分享：我们实验室审了两轮被拒，最后发到了nc。这个期刊很难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=复旦生科院呵呵, createdTime=Fri Jun 11 07:18:19 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968269, encodeId=cb2d968269dc, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：机制明确;癌症;生物信息学 经验分享：至少我们癌症领域很难发，送审率不足10%！之前我们投稿3篇，只送审一篇，有幸中了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=北大科研初学者, createdTime=Mon May 24 22:41:24 CST 2021, time=2021-05-24, status=1, ipAttribution=)]

2022-08-30 ms5000001540302513

偏重的研究方向：感染学;分子诊断
经验分享：昨天投稿目前在编辑审核阶段忐忑

84 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2092121, encodeId=ffa72092121f0, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志是好杂志，但是运气好遇到好的编辑，文章还是有戏的。大部分肿瘤基础研究，被编辑不适合发表在这个杂志而拒你。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:08:41 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242702, encodeId=24ae1242e0241, content=偏重的研究方向：生命科学 经验分享：NAR的效率是真的高，一审两个礼拜就结束了。给了半年修改，返稿之后半天就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6aac5396279, createdName=ms2000000482637756, createdTime=Fri Sep 02 03:10:37 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242046, encodeId=2d661242046e5, content=偏重的研究方向：感染学;分子诊断 经验分享：昨天投稿目前在编辑审核阶段忐忑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=85a68298213, createdName=ms5000001540302513, createdTime=Tue Aug 30 14:13:13 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227981, encodeId=24ca122e98173, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转录因子 经验分享：整天看别人写经验，今天也分享一个。最近投了一篇，很快送外审。外审3周后reject，还没有看到意见，老板出差了。本来想着应该可以修回的，不知道哪里的问题，自我感觉工作还是挺细致的，nature级别的创新性谈不上，但也首次报道了不少发现。估计NAR影响因子不断推高，现在投稿难度相对大了。准备试试其它几个10分以上的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Wed Jun 22 12:56:12 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532867, encodeId=9ce753286e35, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：老牌杂志，评审质量不用说。 2016/10/23凌晨投稿，当天peer-review。 2016/11/16返回审稿意见，一审三周。3个审稿人，问题一大推，不过都是一些值得讨论的问题，总体算是小修。 2017/01/17提交response。慢悠且谨慎的回答了两个月。编辑部来信催稿，就提交了。 2017/02/12返回二审意见（三周），3个审稿人的意见都是quite positive，主编accept。 之前投PNAS被拒，选择NAR主要是因为方向对口且审稿快。 杂志对创新性要求极高，文章机制要明确，内容要夯实，故事要完整。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=630, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60061655700, createdName=Liu Pilong, createdTime=Wed Feb 15 17:08:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005759, encodeId=90211005e59ab, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:3800.0 偏重的研究方向：核酸酶 经验分享：审稿超快，三周审完，修回后一天直接接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210616/5e9e8fc68e154194bb66963fec5de5fe/34d9ec5bc5cf456a8307b5c155f2028c.jpg, createdBy=67fc2107291, createdName=573611573_71677993, createdTime=Sat Aug 07 10:02:52 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074738, encodeId=c38210e4738c1, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：生物信息学;癌症;生命科学 经验分享：要是能在这个杂志发一篇觉得挺牛的，中国人发表不到8%，还是很难发的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 28 11:37:44 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565173, encodeId=9e735651e3f0, content=in editorial review这个状态需要多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Fri Jan 04 00:00:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972732, encodeId=81fd9e2732b3, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：核酸检测;遗传学与生物信息学 经验分享：我们实验室审了两轮被拒，最后发到了nc。这个期刊很难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=复旦生科院呵呵, createdTime=Fri Jun 11 07:18:19 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968269, encodeId=cb2d968269dc, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：机制明确;癌症;生物信息学 经验分享：至少我们癌症领域很难发，送审率不足10%！之前我们投稿3篇，只送审一篇，有幸中了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=北大科研初学者, createdTime=Mon May 24 22:41:24 CST 2021, time=2021-05-24, status=1, ipAttribution=)]

2022-06-22 franky45

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：转录因子
经验分享：整天看别人写经验，今天也分享一个。最近投了一篇，很快送外审。外审3周后reject，还没有看到意见，老板出差了。本来想着应该可以修回的，不知道哪里的问题，自我感觉工作还是挺细致的，nature级别的创新性谈不上，但也首次报道了不少发现。估计NAR影响因子不断推高，现在投稿难度相对大了。准备试试其它几个10分以上的杂志。

62 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2092121, encodeId=ffa72092121f0, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志是好杂志，但是运气好遇到好的编辑，文章还是有戏的。大部分肿瘤基础研究，被编辑不适合发表在这个杂志而拒你。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:08:41 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242702, encodeId=24ae1242e0241, content=偏重的研究方向：生命科学 经验分享：NAR的效率是真的高，一审两个礼拜就结束了。给了半年修改，返稿之后半天就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6aac5396279, createdName=ms2000000482637756, createdTime=Fri Sep 02 03:10:37 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242046, encodeId=2d661242046e5, content=偏重的研究方向：感染学;分子诊断 经验分享：昨天投稿目前在编辑审核阶段忐忑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=85a68298213, createdName=ms5000001540302513, createdTime=Tue Aug 30 14:13:13 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227981, encodeId=24ca122e98173, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转录因子 经验分享：整天看别人写经验，今天也分享一个。最近投了一篇，很快送外审。外审3周后reject，还没有看到意见，老板出差了。本来想着应该可以修回的，不知道哪里的问题，自我感觉工作还是挺细致的，nature级别的创新性谈不上，但也首次报道了不少发现。估计NAR影响因子不断推高，现在投稿难度相对大了。准备试试其它几个10分以上的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Wed Jun 22 12:56:12 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532867, encodeId=9ce753286e35, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：老牌杂志，评审质量不用说。 2016/10/23凌晨投稿，当天peer-review。 2016/11/16返回审稿意见，一审三周。3个审稿人，问题一大推，不过都是一些值得讨论的问题，总体算是小修。 2017/01/17提交response。慢悠且谨慎的回答了两个月。编辑部来信催稿，就提交了。 2017/02/12返回二审意见（三周），3个审稿人的意见都是quite positive，主编accept。 之前投PNAS被拒，选择NAR主要是因为方向对口且审稿快。 杂志对创新性要求极高，文章机制要明确，内容要夯实，故事要完整。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=630, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60061655700, createdName=Liu Pilong, createdTime=Wed Feb 15 17:08:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005759, encodeId=90211005e59ab, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:3800.0 偏重的研究方向：核酸酶 经验分享：审稿超快，三周审完，修回后一天直接接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210616/5e9e8fc68e154194bb66963fec5de5fe/34d9ec5bc5cf456a8307b5c155f2028c.jpg, createdBy=67fc2107291, createdName=573611573_71677993, createdTime=Sat Aug 07 10:02:52 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074738, encodeId=c38210e4738c1, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：生物信息学;癌症;生命科学 经验分享：要是能在这个杂志发一篇觉得挺牛的，中国人发表不到8%，还是很难发的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 28 11:37:44 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565173, encodeId=9e735651e3f0, content=in editorial review这个状态需要多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Fri Jan 04 00:00:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972732, encodeId=81fd9e2732b3, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：核酸检测;遗传学与生物信息学 经验分享：我们实验室审了两轮被拒，最后发到了nc。这个期刊很难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=复旦生科院呵呵, createdTime=Fri Jun 11 07:18:19 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968269, encodeId=cb2d968269dc, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：机制明确;癌症;生物信息学 经验分享：至少我们癌症领域很难发，送审率不足10%！之前我们投稿3篇，只送审一篇，有幸中了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=北大科研初学者, createdTime=Mon May 24 22:41:24 CST 2021, time=2021-05-24, status=1, ipAttribution=)]

2017-02-15 Liu Pilong

审稿速度:1.0 | 投稿命中率:5.0
经验分享：老牌杂志，评审质量不用说。

2016/10/23凌晨投稿，当天peer-review。
2016/11/16返回审稿意见，一审三周。3个审稿人，问题一大推，不过都是一些值得讨论的问题，总体算是小修。
2017/01/17提交response。慢悠且谨慎的回答了两个月。编辑部来信催稿，就提交了。
2017/02/12返回二审意见（三周），3个审稿人的意见都是quite positive，主编accept。

之前投PNAS被拒，选择NAR主要是因为方向对口且审稿快。

杂志对创新性要求极高，文章机制要明确，内容要夯实，故事要完整。

630 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2092121, encodeId=ffa72092121f0, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志是好杂志，但是运气好遇到好的编辑，文章还是有戏的。大部分肿瘤基础研究，被编辑不适合发表在这个杂志而拒你。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:08:41 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242702, encodeId=24ae1242e0241, content=偏重的研究方向：生命科学 经验分享：NAR的效率是真的高，一审两个礼拜就结束了。给了半年修改，返稿之后半天就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6aac5396279, createdName=ms2000000482637756, createdTime=Fri Sep 02 03:10:37 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242046, encodeId=2d661242046e5, content=偏重的研究方向：感染学;分子诊断 经验分享：昨天投稿目前在编辑审核阶段忐忑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=85a68298213, createdName=ms5000001540302513, createdTime=Tue Aug 30 14:13:13 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227981, encodeId=24ca122e98173, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转录因子 经验分享：整天看别人写经验，今天也分享一个。最近投了一篇，很快送外审。外审3周后reject，还没有看到意见，老板出差了。本来想着应该可以修回的，不知道哪里的问题，自我感觉工作还是挺细致的，nature级别的创新性谈不上，但也首次报道了不少发现。估计NAR影响因子不断推高，现在投稿难度相对大了。准备试试其它几个10分以上的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Wed Jun 22 12:56:12 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532867, encodeId=9ce753286e35, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：老牌杂志，评审质量不用说。 2016/10/23凌晨投稿，当天peer-review。 2016/11/16返回审稿意见，一审三周。3个审稿人，问题一大推，不过都是一些值得讨论的问题，总体算是小修。 2017/01/17提交response。慢悠且谨慎的回答了两个月。编辑部来信催稿，就提交了。 2017/02/12返回二审意见（三周），3个审稿人的意见都是quite positive，主编accept。 之前投PNAS被拒，选择NAR主要是因为方向对口且审稿快。 杂志对创新性要求极高，文章机制要明确，内容要夯实，故事要完整。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=630, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60061655700, createdName=Liu Pilong, createdTime=Wed Feb 15 17:08:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005759, encodeId=90211005e59ab, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:3800.0 偏重的研究方向：核酸酶 经验分享：审稿超快，三周审完，修回后一天直接接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210616/5e9e8fc68e154194bb66963fec5de5fe/34d9ec5bc5cf456a8307b5c155f2028c.jpg, createdBy=67fc2107291, createdName=573611573_71677993, createdTime=Sat Aug 07 10:02:52 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074738, encodeId=c38210e4738c1, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：生物信息学;癌症;生命科学 经验分享：要是能在这个杂志发一篇觉得挺牛的，中国人发表不到8%，还是很难发的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 28 11:37:44 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565173, encodeId=9e735651e3f0, content=in editorial review这个状态需要多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Fri Jan 04 00:00:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972732, encodeId=81fd9e2732b3, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：核酸检测;遗传学与生物信息学 经验分享：我们实验室审了两轮被拒，最后发到了nc。这个期刊很难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=复旦生科院呵呵, createdTime=Fri Jun 11 07:18:19 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968269, encodeId=cb2d968269dc, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：机制明确;癌症;生物信息学 经验分享：至少我们癌症领域很难发，送审率不足10%！之前我们投稿3篇，只送审一篇，有幸中了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=北大科研初学者, createdTime=Mon May 24 22:41:24 CST 2021, time=2021-05-24, status=1, ipAttribution=)]

2021-08-07 573611573_71677993

审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:3800.0
偏重的研究方向：核酸酶
经验分享：审稿超快，三周审完，修回后一天直接接收

147 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2092121, encodeId=ffa72092121f0, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志是好杂志，但是运气好遇到好的编辑，文章还是有戏的。大部分肿瘤基础研究，被编辑不适合发表在这个杂志而拒你。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:08:41 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242702, encodeId=24ae1242e0241, content=偏重的研究方向：生命科学 经验分享：NAR的效率是真的高，一审两个礼拜就结束了。给了半年修改，返稿之后半天就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6aac5396279, createdName=ms2000000482637756, createdTime=Fri Sep 02 03:10:37 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242046, encodeId=2d661242046e5, content=偏重的研究方向：感染学;分子诊断 经验分享：昨天投稿目前在编辑审核阶段忐忑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=85a68298213, createdName=ms5000001540302513, createdTime=Tue Aug 30 14:13:13 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227981, encodeId=24ca122e98173, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转录因子 经验分享：整天看别人写经验，今天也分享一个。最近投了一篇，很快送外审。外审3周后reject，还没有看到意见，老板出差了。本来想着应该可以修回的，不知道哪里的问题，自我感觉工作还是挺细致的，nature级别的创新性谈不上，但也首次报道了不少发现。估计NAR影响因子不断推高，现在投稿难度相对大了。准备试试其它几个10分以上的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Wed Jun 22 12:56:12 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532867, encodeId=9ce753286e35, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：老牌杂志，评审质量不用说。 2016/10/23凌晨投稿，当天peer-review。 2016/11/16返回审稿意见，一审三周。3个审稿人，问题一大推，不过都是一些值得讨论的问题，总体算是小修。 2017/01/17提交response。慢悠且谨慎的回答了两个月。编辑部来信催稿，就提交了。 2017/02/12返回二审意见（三周），3个审稿人的意见都是quite positive，主编accept。 之前投PNAS被拒，选择NAR主要是因为方向对口且审稿快。 杂志对创新性要求极高，文章机制要明确，内容要夯实，故事要完整。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=630, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60061655700, createdName=Liu Pilong, createdTime=Wed Feb 15 17:08:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005759, encodeId=90211005e59ab, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:3800.0 偏重的研究方向：核酸酶 经验分享：审稿超快，三周审完，修回后一天直接接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210616/5e9e8fc68e154194bb66963fec5de5fe/34d9ec5bc5cf456a8307b5c155f2028c.jpg, createdBy=67fc2107291, createdName=573611573_71677993, createdTime=Sat Aug 07 10:02:52 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074738, encodeId=c38210e4738c1, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：生物信息学;癌症;生命科学 经验分享：要是能在这个杂志发一篇觉得挺牛的，中国人发表不到8%，还是很难发的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 28 11:37:44 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565173, encodeId=9e735651e3f0, content=in editorial review这个状态需要多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Fri Jan 04 00:00:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972732, encodeId=81fd9e2732b3, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：核酸检测;遗传学与生物信息学 经验分享：我们实验室审了两轮被拒，最后发到了nc。这个期刊很难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=复旦生科院呵呵, createdTime=Fri Jun 11 07:18:19 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968269, encodeId=cb2d968269dc, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：机制明确;癌症;生物信息学 经验分享：至少我们癌症领域很难发，送审率不足10%！之前我们投稿3篇，只送审一篇，有幸中了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=北大科研初学者, createdTime=Mon May 24 22:41:24 CST 2021, time=2021-05-24, status=1, ipAttribution=)]

2021-11-28 slientwo

审稿速度:1.0 | 投稿命中率:5.0
偏重的研究方向：生物信息学;癌症;生命科学
经验分享：要是能在这个杂志发一篇觉得挺牛的，中国人发表不到8%，还是很难发的。

74 0

[GetPortalCommentsPageByObjectIdResponse(id=2092121, encodeId=ffa72092121f0, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志是好杂志，但是运气好遇到好的编辑，文章还是有戏的。大部分肿瘤基础研究，被编辑不适合发表在这个杂志而拒你。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:08:41 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242702, encodeId=24ae1242e0241, content=偏重的研究方向：生命科学 经验分享：NAR的效率是真的高，一审两个礼拜就结束了。给了半年修改，返稿之后半天就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6aac5396279, createdName=ms2000000482637756, createdTime=Fri Sep 02 03:10:37 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242046, encodeId=2d661242046e5, content=偏重的研究方向：感染学;分子诊断 经验分享：昨天投稿目前在编辑审核阶段忐忑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=85a68298213, createdName=ms5000001540302513, createdTime=Tue Aug 30 14:13:13 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227981, encodeId=24ca122e98173, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转录因子 经验分享：整天看别人写经验，今天也分享一个。最近投了一篇，很快送外审。外审3周后reject，还没有看到意见，老板出差了。本来想着应该可以修回的，不知道哪里的问题，自我感觉工作还是挺细致的，nature级别的创新性谈不上，但也首次报道了不少发现。估计NAR影响因子不断推高，现在投稿难度相对大了。准备试试其它几个10分以上的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Wed Jun 22 12:56:12 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532867, encodeId=9ce753286e35, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：老牌杂志，评审质量不用说。 2016/10/23凌晨投稿，当天peer-review。 2016/11/16返回审稿意见，一审三周。3个审稿人，问题一大推，不过都是一些值得讨论的问题，总体算是小修。 2017/01/17提交response。慢悠且谨慎的回答了两个月。编辑部来信催稿，就提交了。 2017/02/12返回二审意见（三周），3个审稿人的意见都是quite positive，主编accept。 之前投PNAS被拒，选择NAR主要是因为方向对口且审稿快。 杂志对创新性要求极高，文章机制要明确，内容要夯实，故事要完整。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=630, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60061655700, createdName=Liu Pilong, createdTime=Wed Feb 15 17:08:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005759, encodeId=90211005e59ab, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:3800.0 偏重的研究方向：核酸酶 经验分享：审稿超快，三周审完，修回后一天直接接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210616/5e9e8fc68e154194bb66963fec5de5fe/34d9ec5bc5cf456a8307b5c155f2028c.jpg, createdBy=67fc2107291, createdName=573611573_71677993, createdTime=Sat Aug 07 10:02:52 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074738, encodeId=c38210e4738c1, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：生物信息学;癌症;生命科学 经验分享：要是能在这个杂志发一篇觉得挺牛的，中国人发表不到8%，还是很难发的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 28 11:37:44 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565173, encodeId=9e735651e3f0, content=in editorial review这个状态需要多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Fri Jan 04 00:00:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972732, encodeId=81fd9e2732b3, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：核酸检测;遗传学与生物信息学 经验分享：我们实验室审了两轮被拒，最后发到了nc。这个期刊很难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=复旦生科院呵呵, createdTime=Fri Jun 11 07:18:19 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968269, encodeId=cb2d968269dc, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：机制明确;癌症;生物信息学 经验分享：至少我们癌症领域很难发，送审率不足10%！之前我们投稿3篇，只送审一篇，有幸中了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=北大科研初学者, createdTime=Mon May 24 22:41:24 CST 2021, time=2021-05-24, status=1, ipAttribution=)]

2019-01-04 tomsyu

in editorial review这个状态需要多久啊？

300 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2092121, encodeId=ffa72092121f0, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志是好杂志，但是运气好遇到好的编辑，文章还是有戏的。大部分肿瘤基础研究，被编辑不适合发表在这个杂志而拒你。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:08:41 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242702, encodeId=24ae1242e0241, content=偏重的研究方向：生命科学 经验分享：NAR的效率是真的高，一审两个礼拜就结束了。给了半年修改，返稿之后半天就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6aac5396279, createdName=ms2000000482637756, createdTime=Fri Sep 02 03:10:37 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242046, encodeId=2d661242046e5, content=偏重的研究方向：感染学;分子诊断 经验分享：昨天投稿目前在编辑审核阶段忐忑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=85a68298213, createdName=ms5000001540302513, createdTime=Tue Aug 30 14:13:13 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227981, encodeId=24ca122e98173, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转录因子 经验分享：整天看别人写经验，今天也分享一个。最近投了一篇，很快送外审。外审3周后reject，还没有看到意见，老板出差了。本来想着应该可以修回的，不知道哪里的问题，自我感觉工作还是挺细致的，nature级别的创新性谈不上，但也首次报道了不少发现。估计NAR影响因子不断推高，现在投稿难度相对大了。准备试试其它几个10分以上的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Wed Jun 22 12:56:12 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532867, encodeId=9ce753286e35, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：老牌杂志，评审质量不用说。 2016/10/23凌晨投稿，当天peer-review。 2016/11/16返回审稿意见，一审三周。3个审稿人，问题一大推，不过都是一些值得讨论的问题，总体算是小修。 2017/01/17提交response。慢悠且谨慎的回答了两个月。编辑部来信催稿，就提交了。 2017/02/12返回二审意见（三周），3个审稿人的意见都是quite positive，主编accept。 之前投PNAS被拒，选择NAR主要是因为方向对口且审稿快。 杂志对创新性要求极高，文章机制要明确，内容要夯实，故事要完整。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=630, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60061655700, createdName=Liu Pilong, createdTime=Wed Feb 15 17:08:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005759, encodeId=90211005e59ab, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:3800.0 偏重的研究方向：核酸酶 经验分享：审稿超快，三周审完，修回后一天直接接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210616/5e9e8fc68e154194bb66963fec5de5fe/34d9ec5bc5cf456a8307b5c155f2028c.jpg, createdBy=67fc2107291, createdName=573611573_71677993, createdTime=Sat Aug 07 10:02:52 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074738, encodeId=c38210e4738c1, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：生物信息学;癌症;生命科学 经验分享：要是能在这个杂志发一篇觉得挺牛的，中国人发表不到8%，还是很难发的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 28 11:37:44 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565173, encodeId=9e735651e3f0, content=in editorial review这个状态需要多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Fri Jan 04 00:00:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972732, encodeId=81fd9e2732b3, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：核酸检测;遗传学与生物信息学 经验分享：我们实验室审了两轮被拒，最后发到了nc。这个期刊很难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=复旦生科院呵呵, createdTime=Fri Jun 11 07:18:19 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968269, encodeId=cb2d968269dc, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：机制明确;癌症;生物信息学 经验分享：至少我们癌症领域很难发，送审率不足10%！之前我们投稿3篇，只送审一篇，有幸中了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=北大科研初学者, createdTime=Mon May 24 22:41:24 CST 2021, time=2021-05-24, status=1, ipAttribution=)]

2021-06-11 复旦生科院呵呵

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：核酸检测;遗传学与生物信息学
经验分享：我们实验室审了两轮被拒，最后发到了nc。这个期刊很难

201 0

[GetPortalCommentsPageByObjectIdResponse(id=2092121, encodeId=ffa72092121f0, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志是好杂志，但是运气好遇到好的编辑，文章还是有戏的。大部分肿瘤基础研究，被编辑不适合发表在这个杂志而拒你。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:08:41 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242702, encodeId=24ae1242e0241, content=偏重的研究方向：生命科学 经验分享：NAR的效率是真的高，一审两个礼拜就结束了。给了半年修改，返稿之后半天就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6aac5396279, createdName=ms2000000482637756, createdTime=Fri Sep 02 03:10:37 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242046, encodeId=2d661242046e5, content=偏重的研究方向：感染学;分子诊断 经验分享：昨天投稿目前在编辑审核阶段忐忑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=85a68298213, createdName=ms5000001540302513, createdTime=Tue Aug 30 14:13:13 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227981, encodeId=24ca122e98173, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转录因子 经验分享：整天看别人写经验，今天也分享一个。最近投了一篇，很快送外审。外审3周后reject，还没有看到意见，老板出差了。本来想着应该可以修回的，不知道哪里的问题，自我感觉工作还是挺细致的，nature级别的创新性谈不上，但也首次报道了不少发现。估计NAR影响因子不断推高，现在投稿难度相对大了。准备试试其它几个10分以上的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Wed Jun 22 12:56:12 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532867, encodeId=9ce753286e35, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：老牌杂志，评审质量不用说。 2016/10/23凌晨投稿，当天peer-review。 2016/11/16返回审稿意见，一审三周。3个审稿人，问题一大推，不过都是一些值得讨论的问题，总体算是小修。 2017/01/17提交response。慢悠且谨慎的回答了两个月。编辑部来信催稿，就提交了。 2017/02/12返回二审意见（三周），3个审稿人的意见都是quite positive，主编accept。 之前投PNAS被拒，选择NAR主要是因为方向对口且审稿快。 杂志对创新性要求极高，文章机制要明确，内容要夯实，故事要完整。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=630, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60061655700, createdName=Liu Pilong, createdTime=Wed Feb 15 17:08:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005759, encodeId=90211005e59ab, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:3800.0 偏重的研究方向：核酸酶 经验分享：审稿超快，三周审完，修回后一天直接接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210616/5e9e8fc68e154194bb66963fec5de5fe/34d9ec5bc5cf456a8307b5c155f2028c.jpg, createdBy=67fc2107291, createdName=573611573_71677993, createdTime=Sat Aug 07 10:02:52 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074738, encodeId=c38210e4738c1, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：生物信息学;癌症;生命科学 经验分享：要是能在这个杂志发一篇觉得挺牛的，中国人发表不到8%，还是很难发的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 28 11:37:44 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565173, encodeId=9e735651e3f0, content=in editorial review这个状态需要多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Fri Jan 04 00:00:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972732, encodeId=81fd9e2732b3, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：核酸检测;遗传学与生物信息学 经验分享：我们实验室审了两轮被拒，最后发到了nc。这个期刊很难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=复旦生科院呵呵, createdTime=Fri Jun 11 07:18:19 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968269, encodeId=cb2d968269dc, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：机制明确;癌症;生物信息学 经验分享：至少我们癌症领域很难发，送审率不足10%！之前我们投稿3篇，只送审一篇，有幸中了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=北大科研初学者, createdTime=Mon May 24 22:41:24 CST 2021, time=2021-05-24, status=1, ipAttribution=)]

2021-05-24 北大科研初学者

审稿速度:1.0 | 投稿命中率:5.0
偏重的研究方向：机制明确;癌症;生物信息学
经验分享：至少我们癌症领域很难发，送审率不足10%！之前我们投稿3篇，只送审一篇，有幸中了！

101 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务